Monopar Therapeutics Inc. (NASDAQ:MNPR) Receives Average Rating of “Moderate Buy” from Analysts

Monopar Therapeutics Inc. (NASDAQ:MNPR) has been assigned a consensus recommendation of “Moderate Buy” from the thirteen research firms that are currently covering the stock, MarketBeat.com reports. One equities research analyst has rated the stock with a sell recommendation, two have given a hold recommendation, eight have issued a buy recommendation and two have issued a strong buy recommendation on the company. The average 1 year target price among brokerages that have updated their coverage on the stock in the last year is $121.3636.

A number of equities research analysts have recently commented on the stock. Zacks Research downgraded shares of Monopar Therapeutics from a “strong-buy” rating to a “hold” rating in a report on Thursday, August 13th. Morgan Stanley reaffirmed an “overweight” rating and issued a $130.00 price objective on shares of Monopar Therapeutics in a research report on Monday, August 17th. BTIG Research increased their price target on Monopar Therapeutics from $117.00 to $133.00 and gave the company a “buy” rating in a report on Wednesday, August 12th. Piper Sandler set a $105.00 price objective on shares of Monopar Therapeutics in a research report on Tuesday, June 2nd. Finally, HC Wainwright lifted their target price on Monopar Therapeutics from $105.00 to $125.00 and gave the stock a “buy” rating in a research report on Wednesday, July 22nd.

Insider Buying and Selling

In related news, Director Kim Tsuchimoto sold 4,090 shares of Monopar Therapeutics stock in a transaction on Wednesday, August 26th. The shares were sold at an average price of $111.39, for a total value of $455,585.10. Following the completion of the sale, the director owned 7,396 shares in the company, valued at approximately $823,840.44. The trade was a 35.61% decrease in their ownership of the stock. The sale was disclosed in a filing with the Securities & Exchange Commission, which is accessible through this link. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Also, Director Raymond Anderson sold 3,142 shares of the business’s stock in a transaction dated Tuesday, August 25th. The stock was sold at an average price of $111.77, for a total transaction of $351,181.34. Following the completion of the sale, the director directly owned 23,751 shares of the company’s stock, valued at $2,654,649.27. The trade was a 11.68% decrease in their position. The SEC filing for this sale provides additional information. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. 9.70% of the stock is currently owned by company insiders.

Institutional Investors Weigh In On Monopar Therapeutics

Institutional investors have recently modified their holdings of the business. Bank of New York Mellon Corp bought a new position in Monopar Therapeutics during the second quarter valued at about $7,124,000. Walleye Capital LLC acquired a new position in Monopar Therapeutics during the first quarter valued at approximately $3,458,000. Siren L.L.C. raised its holdings in Monopar Therapeutics by 27.2% in the 1st quarter. Siren L.L.C. now owns 270,118 shares of the company’s stock worth $14,800,000 after acquiring an additional 57,820 shares during the period. Bank of America Corp DE increased its stake in shares of Monopar Therapeutics by 838.2% in the first quarter. Bank of America Corp DE now owns 59,699 shares of the company’s stock worth $3,271,000 after purchasing an additional 53,336 shares during the period. Finally, ADAR1 Capital Management LLC increased its holdings in shares of Monopar Therapeutics by 13.0% during the 1st quarter. ADAR1 Capital Management LLC now owns 264,278 shares of the company’s stock worth $14,480,000 after purchasing an additional 30,370 shares during the period. Institutional investors own 1.83% of the company’s stock.

Monopar Therapeutics Price Performance

Monopar Therapeutics stock opened at $96.63 on Wednesday. The business has a 50 day simple moving average of $111.51 and a 200-day simple moving average of $81.50. The stock has a market capitalization of $648.39 million, a PE ratio of -44.53 and a beta of 1.49. Monopar Therapeutics has a 12 month low of $50.07 and a 12 month high of $124.82.

Monopar Therapeutics (NASDAQ:MNPR) last released its quarterly earnings results on Wednesday, August 12th. The company reported ($0.62) earnings per share for the quarter, topping analysts’ consensus estimates of ($0.64) by $0.02. As a group, equities research analysts anticipate that Monopar Therapeutics will post -2.98 EPS for the current year.

Monopar Therapeutics Company Profile

Monopar Therapeutics Inc is a clinical-stage biopharmaceutical company focused on developing novel treatments for cancer. The company’s programs are designed to address significant limitations associated with existing cancer therapies, including treatment resistance and dose-limiting toxicity.

Monopar’s lead clinical program is camsirubicin, an investigational next-generation anthracycline being developed for patients with advanced soft tissue sarcoma. The drug is designed to retain the anticancer activity of anthracyclines while reducing the risk of cumulative heart damage associated with conventional doxorubicin.